Table 5.

Demographic and clinical characteristics of the experimental groups.

Variable	SCHZ (n = 30)	HC (n = 25)	p-value
	Mean (SD)	Mean (SD)
Gender (F/M)	10/20	10/15	0.817
Age (years)	32 (9.1)	31.57 (7.57)	0.837
Education (years)	14.11 (2.64)	14.28 (2.15)	0.777
PANSS total score	37.6 (7.43)
PANSS positive symptoms	8.18 (1.1)
PANSS negative symptoms	11.06 (4.7)
PANSS general symptoms	18.53 (3.03)
CPT omissions	55.43 (14.84)	47.15 (4.63)	0.017
CPT perseverations	54.84 (11.55)	48.61 (7.81)	0.015
CPT commissions	54.62 (9.72)	53.15 (10.99)	0.583
CHLPMZ equivalent	399.1 (182.14)
Duration of untreated psychosis (months)	5.12 (8.03)
Duration of illness (months)	133.72 (170.45)
Ratio of individual SCHZ diagnoses	F20 (n = 20); F23 (n = 10); F25 (n = 0)

CHLPMZ Chlorpromazine.